Skip to content
Aminoscope
Head-to-head

Ecnoglutide vs Semaglutide

A cAMP-biased GLP-1 approved in China against the molecule that defined the class — same target, deliberately different signaling, very different regulatory reach.

By Julian RothResearch & dataUpdated October 2026

Short answer

Only semaglutide is FDA-approved; ecnoglutide is still investigational in the US. Semaglutide suits a reader who puts weight on FDA approval, while ecnoglutide is marketed for weight loss and type 2 diabetes. On the evidence, ecnoglutide has human clinical data and semaglutide has approval-level evidence.

Ecnoglutide

Clinical data

A cAMP-biased GLP-1 agonist engineered to reduce β-arrestin recruitment and desensitization; now NMPA-approved in China for type-2 diabetes and chronic weight management, but still unapproved in the US or EU.

Full Ecnoglutide evidence review

Semaglutide

Wegovy / Ozempic

FDA-approved

~15% mean weight loss in STEP 1; the benchmark that opened modern obesity medicine.

Full Semaglutide evidence review

Ecnoglutide vs Semaglutide: head to head

FDA status / approved use

Ecnoglutide

Approved in China for type 2 diabetes and weight management (2026); not approved in the US or EU

Semaglutide

FDA-approved
Marketed for

Ecnoglutide

Weight loss, type-2 diabetes

Semaglutide

Weight loss, type-2 diabetes
Outcome areas

Ecnoglutide

Weight loss / appetite; Blood sugar / insulin sensitivity

Semaglutide

Weight loss / appetite; Blood sugar / insulin sensitivity
Evidence grade

Ecnoglutide

Clinical data

Semaglutide

FDA-approved
How it works

Ecnoglutide

GLP-1 receptor agonist biased toward cAMP signaling over beta-arrestin

Semaglutide

GLP-1 receptor agonist
Route and dosing

Ecnoglutide

Subcutaneous injection, once weekly

Semaglutide

Subcutaneous, once weekly (Wegovy label); maintenance 2.4 mg (recommended) or 1.7 mg once weekly
Headline human result

Ecnoglutide

Weight change of −13.2% at 2.4 mg vs +0.1% on placebo at week 40 in a 2025 Chinese phase 3 trial

Semaglutide

14.9% mean weight loss vs 2.4% on placebo at 68 weeks (STEP 1, 2.4 mg weekly)
Strongest evidence

Ecnoglutide

Phase 2/3 efficacy RCT, 2025Ecnoglutide evidence reviewPubMed 40555243

Semaglutide

STEP 1, NEJM 2021Semaglutide evidence reviewPubMed 33567185
Key safety signal

Ecnoglutide

Gastrointestinal side effects are the dominant, dose-related tolerability issue

Semaglutide

Nausea, vomiting and constipation, mainly when the dose is raised too quickly
How it is obtained

Ecnoglutide

Legitimately available only inside clinical trials; vials sold online are gray-market research chemicals

Semaglutide

Prescription. Manufacturer self-pay for Wegovy (injection pen) runs $349–$399 per fill, against a $1,349 list priceWegovy cost breakdown

marks a row where the two differ. “Not established” marks a cell the available evidence does not answer. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.

FDA-approved:
Approved by the FDA for a defined indication, on the strength of pivotal human trials.
Clinical data:
Tested in humans — but investigational, discontinued, or proven only on a surrogate marker (not the marketed outcome).

Our verdict

Both are approved, but not in the same places, and that is the whole practical difference: semaglutide is approved in the US and EU, while ecnoglutide’s approvals are China’s NMPA — type 2 diabetes in January 2026 and chronic weight management — with no US or EU authorization. Ecnoglutide is engineered to bias signaling toward cAMP and away from β-arrestin recruitment and receptor internalisation, which is a real pharmacological design choice rather than a marketing one. On weight the figures are closer than the reputations suggest but cannot be compared directly: a Chinese phase 3 in 664 adults without diabetes reported −13.2% at week 40 on 2.4 mg against +0.1% on placebo, versus semaglutide’s roughly 15% in STEP 1 over 68 weeks — different populations, durations and endpoints. Semaglutide’s real advantage is not the percentage; it is the outcomes record behind it.

Ecnoglutide fits if

You are following biased agonism as a design strategy, or you are in a market where ecnoglutide is actually approved and available.

Semaglutide fits if

You want the GLP-1 with the deepest evidence base and the widest approval, prescribable now.

Ecnoglutide vs Semaglutide: common questions

Is semaglutide FDA-approved but ecnoglutide not?
Yes. Semaglutide is FDA-approved. Ecnoglutide is approved in China for type 2 diabetes and weight management (2026); not approved in the US or EU.
Which has stronger human evidence, ecnoglutide or semaglutide?
Semaglutide. It has approval-level evidence (key source: STEP 1, NEJM 2021), while ecnoglutide has human clinical data (key source: Phase 2/3 efficacy RCT, 2025).
What are the main safety concerns with ecnoglutide and semaglutide?
With ecnoglutide, gastrointestinal side effects are the dominant, dose-related tolerability issue. For semaglutide, watch for nausea, vomiting and constipation, mainly when the dose is raised too quickly.

Key studies behind each

Ecnoglutide

  1. Guo W, Xu Z, Zou H, Li F, Li Y, Feng J, et al. (2023). Discovery of ecnoglutide - A novel, long-acting, cAMP-biased glucagon-like peptide-1 (GLP-1) analog. Mol Metab. PubMed 37364710
  2. Ji L, Gao L, Xue H, Tian J, Wang K, Jiang H, et al. (2025). Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. PubMed 40555243
  3. Zhu D, Wang W, Tong G, Ma G, Ma J, Han J, et al. (2024). Efficacy and safety of GLP-1 analog ecnoglutide in adults with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 2 trial. Nat Commun. PubMed 39333121
  4. Zhu D, Wang W, Tong G, Ma J, Wen B, Zheng X, et al. (2026). Efficacy and safety of cAMP signalling-biased GLP-1 analogue ecnoglutide monotherapy versus placebo in patients with type 2 diabetes (EECOH-1): a multi-centre, randomised, double-blind, placebo-controlled, phase 3 trial. Nat Commun. PubMed 41501026

Semaglutide

  1. Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. PubMed 33567185
  2. Rubino D, Abrahamsson N, Davies M, et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4). JAMA. PubMed 33755728
  3. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. PubMed 37952131
  4. Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. PubMed 35658024

The full evidence reviews

Related comparisons